Protein losing enteropathy

WikiDoc Resources for Protein losing enteropathy
Articles
Most recent articles on Protein losing enteropathy Most cited articles on Protein losing enteropathy Review articles on Protein losing enteropathy Articles on Protein losing enteropathy in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Protein losing enteropathy Images of Protein losing enteropathy Photos of Protein losing enteropathy Podcasts & MP3s on Protein losing enteropathy Videos on Protein losing enteropathy
Evidence Based Medicine
Cochrane Collaboration on Protein losing enteropathy Bandolier on Protein losing enteropathy TRIP on Protein losing enteropathy
Clinical Trials
Ongoing Trials on Protein losing enteropathy at Clinical Trials.gov Trial results on Protein losing enteropathy Clinical Trials on Protein losing enteropathy at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Protein losing enteropathy NICE Guidance on Protein losing enteropathy NHS PRODIGY Guidance FDA on Protein losing enteropathy CDC on Protein losing enteropathy
Books
Books on Protein losing enteropathy
News
Protein losing enteropathy in the news Be alerted to news on Protein losing enteropathy News trends on Protein losing enteropathy
Commentary
Blogs on Protein losing enteropathy
Definitions
Definitions of Protein losing enteropathy
Patient Resources / Community
Patient resources on Protein losing enteropathy Discussion groups on Protein losing enteropathy Patient Handouts on Protein losing enteropathy Directions to Hospitals Treating Protein losing enteropathy Risk calculators and risk factors for Protein losing enteropathy
Healthcare Provider Resources
Symptoms of Protein losing enteropathy Causes & Risk Factors for Protein losing enteropathy Diagnostic studies for Protein losing enteropathy Treatment of Protein losing enteropathy
Continuing Medical Education (CME)
CME Programs on Protein losing enteropathy
International
Protein losing enteropathy en Espanol Protein losing enteropathy en Francais
Business
Protein losing enteropathy in the Marketplace Patents on Protein losing enteropathy
Experimental / Informatics
List of terms related to Protein losing enteropathy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Synonyms and keywords: Protein loss, protein deficiency, GI protein loss, gastrointestinal protein loss, protein-losing gastroenteropathy, protein-losing gastroenteropathy, gastroenteropathy, gastric protein loss, helicobacter pylori, H pylori, giant hypertrophic gastropathy, menetrier disease, ménétrier, disease, loss of plasma proteins from the gastrointestinal tract, excessive leakage of plasma proteins into the lumen of the gastrointestinal tract, lymphatic obstruction, mucosal disease with erosions, ulcerations, swelling of the legs, peripheral edema, decreased plasma oncotic pressure

Overview

Protein losing enteropathy is the loss of plasma proteins from the gastrointestinal tract caused by an array of abnormalities.

Historical Perspective

• There is no historical significance associated with protein losing enteropathy.

Classification

• There is no classification for protein losing enteropathy according to recent updates.

Pathophysiology

Normally there is a balance between the synthesis and degradation of proteins maintained by a series of interconnected processes in the body. Any condition which disrupts the normal protein stasis where the loss of protein through the gastrointestinal tract exceeds the body’s ability to synthesize proteins failing to compensate for the loss leads to the development of a state of low serum protein called hypoproteinemia.

• Primary gastrointestinal diseases such as inflammatory bowel disease and malignancies initiates a series of abnormal changes leading to the disruption of the protective mucosal layer of the gut resulting in inflammation, erosions and ulcerations of the normal mucosa leading to:
  • Alteration in the mucosal lining of the gut.
  • An increase in the permeability for the previously semi-permeable and non-permeable proteins, leading to excessive protein leakage through gastrointestinal tract.
  • Decrease surface area for protein reabsorption leading to poor reabsorption.
• Non-erosive gastrointestinal conditions such as connective tissue disorders and infectious diseases affecting the mucosa of the gastrointestinal tract causes the leakage of proteins into the lumen of gastrointestinal tract in a similar manner as erosive gastrointestinal diseases.
• Conditions leading to lymphatic obstruction such as lymphomas and other benign or malignant masses causes an increase in the pressure inside the lymphatic system which forces the lymph to leak out of the lymphatic vessels into the lumen of gastrointestinal tract leading to protein loss.

Causes

Most cases of protein losing enteropathy are caused as a result of:

1. Primary gastrointestinal disorders
2. Lymphatic obstruction

Primary Gastrointestinal Diseases

Mucosal Erosions/Ulcerations

Primary gastrointestinal diseases causing erosion or ulceration of the mucosa of the gut leading to fecal loss of proteins such as:

• Inflammatory bowel diseases (Crohn disease, Ulcerative colitis)
• Malignancies involving the gut mucosa
• Graft vs. host disease
• Esophageal and gastric erosions or ulcerations
• Carcinoid syndrome
• Bacterial infection with Clostridium difficile causing pseudomembranous colitis
• Parasitic infection with Giardia

Non-Erosive/Ulcerative Mucosal involvement

• Celiac disease
• Eosinophilic gastritis
• Hypertrophic gastritis
• Connective tissue disorders: Systemic lupus erythematosus
• Cutaneous burns

Lymphatic Obstruction

Conditions responsible for causing lymphatic obstruction leading to the leakage of lymph into the lumen of gut such as:

• Lymphoma
• Congenital or acquired lymphatic diseases
• Lymphatic filariasis
• Sarcoidosis
• Cardiovascular diseases: Congestive heart failure, Restrictive pericarditis
• Intestinal Tuberculosis
• Fontan surgical procedure
• Cirrhosis with portal hypertension
• Retroperitoneal fibrosis

Complete Differential Diagnosis Of Underlying Causes

Protein losing enteropathy must be differentiated from the following:

• Acute gastroenteritis
• AIDS
• Allergic Gastroenteritis
• Amyloidosis
• Angioedema
• Bacterial overgrowth
• Carcinoid Syndrome
• Celiac Sprue
• Clostridium Difficile
• Congestive Heart Failure
• Connective tissue disorders
• Constrictive pericarditis
• Crohn's Disease
• Duodenal erosions or ulcerations
• Esophageal erosions or ulcerations
• Graft vs. Host Disease
• Henoch-Schonlein Purpura
• Idiopathic ulcerative jejunoileitis
• Intestinal endometriosis
• Intestinal parasites
• Kaposi Sarcoma
• Lymphoenteric fistula
• Lymphoma
• Menetrier's Disease
• Microscopic colitis
• Mucosal-based neoplasm
• Neurofibromatosis
• Protein dyscrasia
• Pseudomembranous colitis
• Retroperitoneal fibrosis
• Sarcoidosis
• Stomach (erosions, ulcerations)
• Tropical sprue
• Tuberculosis
• Ulcerative Colitis
• Whipple's Disease

Diagnosis

As hypoproteinemia is the key factor in evaluating a patient for protein losing enteropathy, other common causes of hypoproteinemia such as nephrotic syndrome, impaired protein synthesis due to chronic liver disease and malnutrition must be excluded first.

Laboratory Studies

As the most prominent laboratory finding is a decrease in serum concentration of albumin and globulin, the diagnostic work up protein losing enteropathy consist of quantitative measurements of Alpha-1 antitrypsin or ⁵¹Cr-albumin.

• Alpha-1 antitrypsin (A1AT) used as an endogenous marker is a sensitive and inexpensive laboratory test performed to diagnose protein losing enteropathy and has become the current standard for quantitating protein losing enteropathy. Measurement of fecal volume and fecal loss of alpha-1 antitrypsin depicts the plasma concentration of alpha-1 antitrypsin as;

• Alpha 1-AT plasma concentration = ((stool volume) x (stool alpha 1-AT)) / (serum alpha-1 AT)

• Gastrointestinal loss of alpha-1 antitrypsin is measured in feces and a clearance greater than 27mL/day is considered diagnostic for protein losing enteropathy.

• 51Cr-labeled albumin can also be measured followed by stool collection to determine the amount of protein loss into the gastrointestinal tract.

Imaging Studies

Following the detection of abnormal amounts of alpha-1 antitrypsin in the stool, the following tests can be performed to detect the specific etiology for the protein loss into the gastrointestinal lumen.

• Administration of technetium-99 labeled macromolecules such as albumin. Imaging is required to localize the primary site of protein leakage with no requirement for fecal collection. Scintigraphy is becoming popular in the diagnosis and localization of the site of protein leakage.  

• For the diagnosis of lymphatic obstruction, computed tomography, lymphangiography or magnetic resonance imaging can be used.

• Radiographic contrast studies and endoscopy can be performed to evaluate the ulcerative or erosive gastrointestinal causes of the protein loss.

• For detecting cardiac diseases causing loss of protein, echocardiography or radionuclide scanning of the heart can be performed.

Other tests:

• All patients should undergo basic laboratory tests such as complete blood test, liver and renal function tests.

• Work up for autoimmune diseases such as systemic lupus erythematosus should be ordered if there is a suspicion of connective tissue disorder causing protein loss in the gastrointestinal tract.

• Biopsy samples of the mucosa and stool cultures for ova and parasites should be performed if there is a suspicion of ulcerative or erosive gastrointestinal disease and parasitic infection, respectively.

Treatment

• Symptomatic relief can be achieved with dietary modifications and medications.

• Supplementation with proteins with 2 to 3 g/kg a day as well as micronutrients, electrolytes and vitamins to compensate for the loss of proteins plays a critical role.

• Treatment with steroids or heparin to stop protein leak via the intestines could also provide symptomatic relief.

• However, protein losing enteropathy is not a separate disease entity but a complication of different pathological conditions and hence the mainstay of treatment depends upon the underlying etiology of the disease causing protein losing enteropathy.

• Effectual treatment depends on a better understanding of the pathophysiology of the disease, for instance, if the underlying pathology involves inflammation or autoimmune condition such as; inflammatory bowel disease or connective tissue disorder, treatment strategy is tailored towards treating the underlying pathology with immunosuppressive medications.

• Similarly, if cardiovascular disease is the underlying pathology of protein losing enteropathy, the mainstay of treatment would be optimization of the medications for heart failure. Diuretics can be used for symptomatic relief.

• Lymphatic obstruction can be relieved according to the underlying etiologies such as; treatment of the parasitic or bacterial infection causing protein losing enteropathy, increased lymphatic pressure can be relieved with octreotide and surgical resection should be considered in case of refractory inflammatory bowel disease.